南财智讯1月29日电，百诚医药公告，公司拟以临平政工出〔2023〕26号文所涉宗地的土地使用权和在 建工程评估作价5849.94万元（不含税），出资设立全资子公司浙江旭沛医药科技有限公司（拟定名， 以工商核准为准）；资金来源为自有资产出资，出资比例100%；新设公司注册资本1000万元，注册地 址为浙江省杭州市临平区；设立目的是丰富研发板块布局、优化业务布局与管理架构、增强核心竞争力 及可持续发展能力；本次投资事项已经公司第四届董事会第九次会议审议通过，无需提交股东大会审 议，不构成重大资产重组，不涉及关联交易；预计对公司财务及经营状况无重大不利影响，不存在损害 上市公司及股东利益的情形。 ...

证券代码：301096 证券简称：百诚医药 公告编号：2026-002 杭州百诚医药科技股份有限公司 关于投资设立全资子公司的公告 1、公司名称：浙江旭沛医药科技有限公司 2、注册地址：浙江省杭州市临平区临平街道绿洲路151-171号（单号）3-3幢 1205室 3、注册资本：1,000万元 4、经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；第一类医疗器械销售；第一类医疗设备租赁；第一类医疗器械生产； 第二类医疗器械销售；第二类医疗设备租赁；化工产品销售（不含许可类化工产品）； 实验分析仪器销售；包装材料及制品销售；气体、液体分离及纯净设备销售；工业设 计服务；软件销售；软件开发；市场营销策划；企业管理咨询；市场调查（不含涉外 调查）；信息技术咨询服务；信息咨询服务（不含许可类信息咨询服务）；会议及展 览服务；货物进出口；技术进出口；股权投资；创业投资（限投资未上市企业）；以 自有资金从事投资活动；自有资金投资的资产管理服务；招投标代理服务；资产评估 (除依法须经批准的项目外，凭营业执照依法自主开展经营活动)。许可项目：第二类 医疗器械生产；第三类医疗器械经营；第三类医疗设 ...

证券代码：301096 证券简称：百诚医药 公告编号：2026-001 杭州百诚医药科技股份有限公司 （一）审议通过《关于投资设立全资子公司的议案》 经董事会审议，根据公司未来业务发展及战略规划需要，丰富研发板块布局， 董事会同意公司以临平政工出〔2023〕26 号文所涉宗地的土地使用权和在建工 程评估作价出资 5,849.94 万元（不含税），投资设立全资子公司浙江旭沛医药 科技有限公司（拟定名，以工商核准为准）（以下简称"浙江旭沛"） ，浙江 旭沛拟定注册资本 1,000 万元，公司持有其 100%股权。 董事会授权公司管理层办理浙江旭沛医药科技有限公司的设立登记事宜。 授权有效期自董事会审议通过之日起至工商设立登记及章程备案办理完毕之日 止。 表决结果：9 票同意，0 票反对，0 票弃权。 具体内容详见公司披露于巨潮资讯网（http://www.cninfo.com.cn）的《关 于投资设立全资子公司的公告》（公告编号：2026-002）。 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、董事会会议召开情 ...

证券日报网讯1月26日，百诚医药（301096）在互动平台回答投资者提问时表示，公司将依托自身在医 药研发领域的技术积累和产业化能力，与国科大杭高院的科研优势相结合，积极推进芳香胺等前沿技术 在产业端的应用。 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2026-01-26 | 301096 | 目诚医药 | 56.00 | 16.08 | | 900.48 东北证券股份有限 | 中信证券股份有限 | | | | | | | | 公司杭州教工路证 | 公司杭州婺江路证 | | | | | | | | 券营业部 | 券营业部 | | 2026-01-26 | 301096 | 百诚医药 | 56.00 | 7.50 | | 420.00 东北证券股份有限 | 中信证券股份有限 | | | | | | | | 公司杭州教工路证 | 公司杭州经汇路证 | | | | | | | | 券营业部 | 劳营业部 | 1月26日，百诚医药大宗交易成交23.58万股，成交额1320.48万元，占当日总成交额的6.8%，成交价56元，较市场收盘价 56.03元折价0.05%。 ...

Summary of Baicheng Pharmaceutical Conference Call Company Overview - **Company**: Baicheng Pharmaceutical - **Date**: January 25, 2026 Key Points Industry and Company Developments - Baicheng Pharmaceutical is committed to innovation and has received multiple clinical approvals for first and second-class new drugs, with expectations for significant performance contributions in the next 2-3 years [2][3] - The company has established a strategic partnership with Italian company Diling to accelerate European GMP certification and overseas CMO/CDMO order acquisition, enjoying priority rights for high-value products in Greater China [2][4] - The generic drug market is expected to see a price recovery in 2026 after a low in Q1 2025, with increased approval standards leading to a concentration in sales [2][6] Financial Performance and Projections - Baicheng Pharmaceutical's sales business is recovering from a low point in Q1 2025, with both demand and pricing showing positive trends [3] - The company has received over 190 approvals for third and fourth-class generic drugs, maintaining stable core operations [3] - Saimo, a subsidiary, won bids for 12 products in the 11th batch of centralized procurement, with substantial order volumes expected to enhance capacity utilization and profitability [2][7] - Sanmu Company is projected to see significant revenue and profit growth in 2026, with overseas market expansion further increasing capacity utilization [2][8] Innovation and Clinical Progress - Baicheng Pharmaceutical's innovation drug segment focuses on CNS, autoimmune diseases, and oncology, with several projects entering clinical stages [2][10] - The 0,118 project for narcolepsy is expected to complete its Phase II trial and report in the first half of the year [2][11] - The company plans to continue investing in its pipeline, with specific projects advancing based on customer interest [11] Strategic Collaborations - The partnership with Diling includes registering high-quality products for European GMP certification and prioritizing clinical submissions in Europe for products requiring extensive clinical trials [4][5] - The financial impact of the collaboration is expected to be minimal in 2026, with commercial orders anticipated post-2027 approval of innovative oral formulations [9] Future Outlook - The chairman of Baicheng Pharmaceutical emphasizes a strong commitment to developing generic drug R&D, CRO business, and expanding Saimo's operations while increasing investment in innovative drug development [12] - The company aims to leverage collaborations with domestic and international clients to launch new products and prioritize strategic international business development, including raw material and formulation exports [12]

Group 1 - The core viewpoint of the news is that Baicheng Pharmaceutical has shown significant fluctuations in its financial performance and stock trading activities, indicating potential investment opportunities and risks [1][2][3] Group 2 - As of January 22, Baicheng Pharmaceutical's stock price increased by 0.37%, with a trading volume of 190 million yuan. The financing buy-in amount was 15.497 million yuan, while the financing repayment was 12.8406 million yuan, resulting in a net financing buy-in of 2.6564 million yuan. The total financing and securities balance reached 363 million yuan [1] - The financing balance of Baicheng Pharmaceutical is 363 million yuan, accounting for 5.81% of its circulating market value, which is above the 80th percentile level over the past year, indicating a high level of financing activity [1] - On the short-selling side, Baicheng Pharmaceutical had a short-selling repayment of 100 shares and no short-selling sales on January 22, with a remaining short-selling volume of 600 shares and a short-selling balance of 34,300 yuan, which is below the 10th percentile level over the past year, indicating low short-selling activity [1] Group 3 - As of September 30, Baicheng Pharmaceutical had 10,100 shareholders, a decrease of 15.05% from the previous period, while the average circulating shares per person increased by 18.15% to 8,242 shares [2] - For the period from January to September 2025, Baicheng Pharmaceutical reported operating revenue of 510 million yuan, a year-on-year decrease of 29.33%, and a net profit attributable to the parent company of 6.1242 million yuan, a year-on-year decrease of 95.68% [2] Group 4 - Baicheng Pharmaceutical has distributed a total of 184 million yuan in dividends since its A-share listing, with 119 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of Baicheng Pharmaceutical saw the exit of the Rongtong Health Industry Flexible Allocation Mixed A/B fund from the list [3]

Core Viewpoint - The company has developed an AI platform for drug research that enhances the precision and efficiency of drug development processes [2] Group 1: AI Platform - The AI platform, referred to as the "Smart Drug AI Platform," is capable of predicting toxicity, activity, and drug-likeness [2] - This platform aims to improve the accuracy and efficiency of drug development [2] Group 2: New Drug Department - The new drug department utilizes an organoid platform that offers drug screening, efficacy evaluation, and safety assessment services [2] - These services are designed to support more precise and efficient drug research [2]

Core Viewpoint - The company is currently not involved in the brain-computer interface sector but will closely monitor developments in this industry [1] Group 1: AI Technology in Drug Development - The company utilizes AI technology in its innovative drug research, specifically in AIDD (Artificial Intelligence Drug Discovery) and CADD (Computer-Aided Drug Design) [1] - The company has developed its own AI platform, known as the Smart Drug AI platform, which can be applied to toxicity prediction as well as activity and drug-likeness prediction [1] Group 2: Organoid Platform and Drug Development Services - The company's organoid platform provides drug development technical services, including drug screening, efficacy evaluation, and safety assessment [1] - This platform aims to enhance the precision and efficiency of drug development processes [1]

Core Viewpoint - The company, Baicheng Pharmaceutical (301096.SZ), is currently not involved in the brain-computer interface sector but will closely monitor developments in this industry [1] Group 1: AI Technology Utilization - The company applies AI technology in innovative drug research, specifically in AIDD (Artificial Intelligence Drug Discovery) and CADD (Computer-Aided Drug Design) [1] - The company has developed its own AI platform, known as the Smart Drug AI platform, which is utilized for toxicity prediction as well as activity and drug-likeness prediction [1] Group 2: Organoid Platform - The company possesses an organoid platform that provides drug development technical services, including drug screening, efficacy evaluation, and safety assessment [1] - This platform aims to enhance the precision and efficiency of drug development processes [1]